Second Circuit says Takeda can’t dodge two antitrust suits

26-08-2021

Alex Baldwin

Second Circuit says Takeda can’t dodge two antitrust suits

Jonathan Weiss / Shutterstock.com

The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.


US Court of Appeals for the Second Circuit, Takeda Pharmaceuticals, Teva Pharmaceuticals, FDA, Actos

LSIPR